As you may know, CBD Capital has been acquired by US-based cannabinoid provider, GenCanna. While this news has been met with excitement, it has also raised questions in some minds because of the financial difficulties the “Old GenCanna” experienced in early 2020. Allow me to address these issues.
Old GenCanna refers to a company that no longer exists. Its assets were acquired by an institutional investor. The only thing “New GenCanna” and “Old GenCanna” have in common is the company’s name, for its seminal pioneering role in this industry. This multibillion-dollar investor infused significant new capital into the New GenCanna, a company that does not include any of Old GenCanna’s liabilities, none of its management team, nor any of its shareholders.
The purpose of this note to you is to highlight some of these fundamental changes and to reassure you that GenCanna is among the best capitalized, most professionally led companies in the cannabinoid business. At CBD Capital, we are proud of this partnership, and we are focused and driven on delivering superior product and extraordinary customer service to merit your business. Our association with GenCanna means a substantial increase in our ability to provide a broad range of product solutions to our customers — in quality, quantities, and delivery speeds we could not have achieved prior to this union. For example, inventory is maintained in our two distribution centers in the UK and the Netherlands, allowing for a less than 24-hour order-to-shipment turnaround. This move is a very good thing, for CBD Capital and our customers.
On June 1, 2020, Andrew Barnett was appointed GenCanna’s new CEO. Andrew has over 40 years of experience transforming and revitalizing companies that include manufacturers, wholesalers and distributors, as well as retailers in food services, HBA, and other consumer product sectors. Andrew has led organizations whose primary goals are to maximize customer satisfaction and profits, and build enterprise value. He has worked in the US, UK, EU, and Asia, and continues to assemble a GenCanna management team of food science, manufacturing, product development, and brand expertise that our industry has yet to see. We are thrilled to be part of it.
NEW CAPITAL & NEW FACILITY
GenCanna’s investor has not only flushed GenCanna with new human and financial capital, it has also financed the construction of a state-of-the-science processing facility that meets all appropriate food safety requirements. Providing the company with absolute control over an optimized seed-to-product supply chain, this 100,000-square-foot facility opens in 4Q21. This plant has no rival in terms of value-added production processes, resulting in the whitest white, non-detect isolate (in various minor forms, including CBD, CBG, CBN, and CBC) as well as distillate, and does so faster and more efficiently than any facility that serves global markets.
NEW VISION & NEW DIRECTION
Further evidence of GenCanna’s commitment on a global scale are the acquisitions of not only CBD Capital, but also London-based CBD finished goods provider Taylor Mammon. The reasoning behind these first two acquisitions is GenCanna’s recognition that the UK, EU, and several other markets provide enormous potential with respect to novel foods and health and wellness products in general. From bulk ingredients for CMOs and consumer brand companies to the highest quality, specialized, and unique white and private label services supporting consumer as well as pet brands and retailers, GenCanna product is unassailable in its integrity, innovation, form factor creativity, speed-to-market, and clockwork delivery. CBD Capital and Taylor Mammon are the pillars for what will be a prudently aggressive expansion across markets served by our UK and EU distribution centers.
In short, it’s a new day for a new GenCanna. We welcome the energy, capabilities, and significant opportunities GenCanna’s strategic vision and leadership bring. Anchored by the formidable capital commitment from our shareholder, it all makes for a new and exciting market, revenue and profit reality for us all — for you, for your customers, and for us at GenCanna.
I welcome your call or email to discuss how we may best serve your needs. And we look forward to expanding our collaboration and partnership with you, helping you deliver excellence to consumers through our outstanding isolate, distillate, and health and wellness products.
American CBD Pioneer GenCanna Acquires CBD Capital
WINCHESTER, KENTUCKY — September 1, 2021— GenCanna (gencanna.com), an industry founding producer of premium full-spectrum and broad-spectrum CBD and other quality cannabinoids for bulk supply and finished goods formulation, announced today that it has acquired CBD Capital Ltd (cbd-capital.com), the leading provider of CBD distillate, isolate, and water-soluble bulk ingredients as well as white and private label services to the United Kingdom, the European Union and markets worldwide. CBD Capital CEO, Hassan Akhtar, will continue to serve in his current role.
The acquisition of CBD Capital enables GenCanna to broaden its bulk CBD product offering and distribution capabilities to its overseas customers, as well as expand its formulation capabilities and business-to-business operations through CBD Capital’s network of valued partners. CBD Capital also brings with it several sub-brands that will now enjoy accelerated product development and market expansion as more resources are devoted to them. The addition of CBD Capital follows GenCanna’s acquisition of London-based CBD finished goods formulator and brand accelerator, Taylor Mammon, further anchoring GenCanna’s footprint across the global CBD market.
“The highly strategic acquisition of CBD Capital widens and solidifies GenCanna’s leadership position across high-growth CBD markets in the United Kingdom, the European Union, and the rest of the world,” said Andrew Barnett, CEO of GenCanna. “As a long-term partner of CBD Capital, we are deeply familiar with its impressive business, which will significantly boost GenCanna’s ability to provide our growing global customer base with deepened and broadened services — such as greater formulation capability and expanded finished goods versatility,
increased supply chain flexibility, and quick-to-market turnaround. We look forward to leveraging CBD Capital’s strong industry experience and passion as we develop end-to-end, turnkey solutions that speed sales and maximize gross margin dollars for our customers. This is the GenCanna way.”
With CBD Capital’s recent opening of a new base in Rotterdam, Netherlands, which facilitates next-day distribution capabilities to markets throughout the European Union, the company is strategically and logistically positioned to further growth and market penetration.
“We are thrilled to join the growing family of GenCanna CBD companies,” said CBD Capital CEO, Hassan Akhtar. “The injection of both financial and human capital, combined with GenCanna’s formidable CBD ingredient extraction and refinement sciences, and its sterling compliance track
record, will now greatly facilitate the expansion and completion of several key channel strategies and market growth initiatives currently within the CBD Capital pipeline.”
About CBD Capital
CBD Capital Ltd. (cbd-capital.com) is a global CBD supplier, distributing internationally-accredited, pharmaceutical grade, wholesale phytocannabinoids to leaders in the global cannabidiol industry. Validated through regulatory accreditations and certifications from multiple governments across the United Kingdom, the European Union, and throughout the world, the company’s state-of-the-art extraction techniques combine with a diverse international supply chain to ensure the provision of industry-competitive, pharmaceutical-grade CBD bulk and finished goods.
About Taylor Mammon
Taylor Mammon Ltd. (taylormammon.com) is a white-label manufacturer and brand distributor of CBD-infused goods. Taylor Mammon sees the benefits in the power of CBD and has created a business model that affords its brand partners total ownership over their brands, while enabling end-consumers to benefit from the exciting applications of CBD. Taylor Mammon continually innovates new products to meet its partners’ rigorous demands.
GenCanna (gencanna.com) is a vertically integrated pioneer-producer of premium hemp-derived CBD and other cannabinoids in both bulk supply as well as in high-quality finished goods formulations. GenCanna’s optimized supply chain is built and operated under the strictest quality assurance standards and regulatory mandates (BRCGS, cGMP), and the company continues to achieve the industry’s most sought-after compliance validations, including the UK’s FSA’s Novel Foods Application. Learn more at gencanna.com/compliance.
European Commission Now Allows Natural CBD in Cosmetics
Back in February 2021, the European Commission (EC) permitted the use of natural CBD in formulating cosmetic products. The decision followed a November 2020 court ruling that the substance was not a narcotic.
The EC’s move has started to bring clarity to a matter that has been confusing many for a long time.
Essentially, EC’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs added two new substances to the EU CosIng database. This is their database containing information about cosmetic substances and ingredients, and their uses.
They include the naturally-derived cannabidiol that comes from the leaf and other parts of the Cannabis Sativa L. plant.
The first entry is CBD derived from extract, resin, or tincture of hemp. Its functions include anti-sebum, anti-oxidant, and skin conditioning and protection.
The second entrant is cannabis sativa leaf extract. Similarly, its functions include skin conditioning and it’s also used as a skin softener.
In late 2020, the European Court of Justice ruled that the entire cannabis plant shouldn’t be classified as a narcotic.
Consequently, the European Industrial Hemp Association (EIHA) moved to request the EC to update the CosIng database.
The Commission granted the plea and added the two CosIng entries for CBD derived from the roots and flowers of cannabis.
Why have these changes been made?
Several professionals and experts in the cosmetics industry have previously said that the regulation concerning CBD products was unclear.
This situation had created a disparity in the compliance of EU member states. However, things are beginning to shift, thanks to the new entries.
Until February 2021, the CosIng database had only permitted synthetic CBD.
However, the EU Cosmetics Regulation (EC No. 1223/2009) allowed the use of CBD derived from leaves, stems, and some other parts of the cannabis plant.
Further confusion arose concerning the hemp flower extracts. While most member states disallowed CBD derived from flowers, some permitted it.
Presently, the CosIng database lists natural CBD derived from cannabis resin or extract and leaves as distinct cosmetic ingredients.
Of course, the catalogue is only informative and doesn’t serve a legal purpose.
However, the CosIng guides the member states and helps to synchronise cosmetic product marketing on the continent.
What’s the difference between synthetic and natural CBD?
So, what exactly is the difference between synthetic and natural CBD? Well, most of the over-the-counter supplements you buy are not organic substances.
While they are made in a laboratory, these compounds are pretty much identical to their natural counterparts.
Similarly, synthetic CBD is manufactured in the lab using chemicals and biomolecules. However, it is bioidentical to the hemp plant-derived cannabidiol. Moreover, it affects the body in the same way its natural counterpart does.
Why, then, has the EU placed strict regulations around the naturally-derived ingredient in the past?
If you manufactured cosmetics from the natural compound, the products would probably contain low CBD concentration.
Worse still, they could have trace tetrahydrocannabinol. Many jurisdictions regard CBD that contains over 0.2% of THC as a narcotic, including the UK.
That’s why several countries in the EU place stringent measures on the sale of CBD-containing products.
On the contrary, EU regulations do not label any synthetic CBD product as a narcotic. They only place restrictions on natural compounds that come from flowers or fruits of the hemp plant.
However, this regulatory framework was complex, even for experts in the cosmetic field.
What does the new development mean?
The addition of the two fresh natural CBD ingredients to the catalogue presents a new era in the cosmetic industry.
First, it clarifies the regulation around the use of these compounds in manufacturing cosmetics. Also, more manufacturers are certainly going to use CBD in production and on a larger scale.
Moreover, the update in the regulation may spark a heavier investment in research, innovation, and development of CBD products.
Bigger cosmetics players are likely going to invest more in developing fresh and independent brands. Also, they could extend their current lines of products.
Consequently, this situation may increase consumer interest and product demand.
Before the change in the EU regulation, manufacturers and marketers had a hard time dealing with the sourcing of CBD and its products.
They had to engage in lengthy and complex talks with several entities before making or marketing these substances. These included investors, regulators, wholesalers, retailers, and payment transactors.
The new regulatory landscape removes barriers from the road of manufacturing and marketing CBD cosmetics. Soon, you are going to see more of these products on the market.
Better still, more consumers are set to benefit from what’s going to be on the counter.
Also, the new regulation could lead to claims validation. In the past, companies have only been able to make general claims.
However, the time has come for them to produce solid evidence about the efficacy of their specific CBD products.
What’s next for CBD cosmetics companies?
This good news for the CBD industry does not mean the game is over.
While the EC updated the CosIng database, it’s important to note that the catalogue is not legally valuable.
This means it is up to each EU Member State to regulate the manufacture and marketing of natural CBD cosmetics.
For instance, the UK recently recognised the CosIng database as an important guide in the country’s regulations.
However, Austria still restricts the marketing of cosmetics containing this natural ingredient.
Also, to sell cosmetic products, you need to conduct safety assessments in line with the Regulation and the CosIng.
Therefore, brands that would use CBD in their cosmetics should consider the amount of time, research, and cost to put in.
These companies must prove beyond any reasonable doubt that these products are safe for humans.
The EC Now Allows Natural CBD In Cosmetics: Conclusion
The inclusion of the two new ingredients in the CosIng database marks a revolution in the CBD cosmetics industry.
Since the catalogue’s function is to coordinate cosmetic product marketing in all EU states, several members are likely to oblige.
As a result, more companies will look to manufacture cosmetics that contain natural CBD – widening the potential of the market.
To find out more about the specific CBD regulations in the UK, check out our guide to CBD oil and UK law. Or, if you’d like to know more about getting into the CBD business, contact us today to find out how we can help you!
Brexit CBD Restrictions: Everything You Need to Know
Brexit has dominated the headlines for the last five years. Now that the UK is no longer in the EU, industries and the economy are starting to feel the effects. Here, we discuss all there is to know about the new Brexit CBD restrictions.
Under these regulations, foods or food ingredients that don’t have a history of consumption prior to May 1997 must be assessed and authorised before they can be marketed.
In February 2020, the Food Standards Agency (FSA) gave UK companies a deadline of 31 March 2021. By then, companies must have a validated novel food application in place for each of their products. Only products linked to such an application would be allowed to remain on the shelves from 1 April 2021.
The FSA recently updated this rule to include products linked to a novel food application that has been submitted (rather than validated) by 31 March 2021. Products can stay on the shelves during the process of validation.
After submitting a novel food application, validation usually takes around 2-3 months. Validation means the applicant has submitted all the necessary information, and the application can move onto the authorisation stage. Full authorisation can take over a year.
Products that weren’t on sale before the FSA’s initial announcement (13 February 2020) must have full novel food authorisation before coming to market.
However, Brexit has complicated novel food regulations for CBD, with Scotland’s pro-EU politics and the Northern Ireland-Republic of Ireland (ROI) border issue complicating the situation.
This has resulted in three different regulatory regimes across the UK. The FSA’s deadline applies to companies in England and Wales, but there are different rules for Scotland and Northern Ireland.
What are the rules in Scotland?
Food safety in Scotland is governed by Food Standards Scotland (FSS), rather than the FSA. FSS has rejected the FSA’s 31 March deadline system and instead opted to follow the EU’s authorisation-only policy.
Because of this, FSS is encouraging a proportionate approach to enforcement, taking into account a company’s commitment to gaining legal compliance.
Despite not aligning with the FSA’s approach of allowing products without full novel food authorisation to stay on the shelves, FSS is working closely with the FSA on the validation and authorisation of novel food applications. Companies only need to submit their applications to the FSA, with no need to submit to FSS separately.
What are the rules in Northern Ireland?
Novel food regulations for Northern Ireland have been complicated by the issue of the post-Brexit border between the UK and EU.
The Northern Ireland Protocol was negotiated by the UK and EU to avoid a hard border between Northern Ireland and the ROI. It enables goods to cross between the two countries with no new checks.
However, Brexit has ended the free movement of goods between the UK and the EU. This is a blow to UK CBD companies. Most companies rely on CBD imported from EU countries that allow hemp growers to use the plant’s flowers. In the UK, hemp flowers are a controlled substance.
As the UK is no longer required to follow EU regulations on product standards, companies are facing new customs checks and more paperwork. This can make shipping goods – including CBD products – much more complicated.
These new difficulties can create extra costs and shipping delays, putting a strain on supply chain relationships. Many CBD companies are already experiencing issues; some shipments being held up at customs or turned away at the border because they don’t have the correct documents.
The danger is that these new challenges may force UK companies to drop their European CBD suppliers and look elsewhere.
Could Brexit bring benefits for the CBD industry?
No longer bound by EU regulations, some believe that Brexit may unlock new opportunities for the UK CBD industry. For example, it may make it possible to develop a CBD sector similar to Switzerland’s, which is thriving.
‘CBD is Not a Narcotic’ says EU Court in CBD Breakthrough
In an exciting development in CBD oil news, the EU’s highest court has ruled that CBD is not a narcotic.
This landmark decision has provided a welcome boost for the European CBD industry, creating a clearer path to full legal compliance for CBD companies.
The latest CBD oil news: CBD is not a narcotic
The ruling by the Court of Justice of the European Union (CJEU) was announced on 19 November 2020. It states that cannabidiol (CBD) is not a narcotic drug because it ‘does not appear to have any psychotropic effect or any harmful effect on human health’.
The ruling came as part of a case known as the ‘KanaVape Case’, which involved the prosecution of French CBD company KanaVape.
KanaVape sold e-cigarettes containing CBD oil derived from whole hemp plants. In French law, only the seeds and fibre of hemp may be used commercially – it’s illegal to use the buds or flowers. CBD oil and UK law are similar in this aspect.
However, the CBD that KanaVape used was produced lawfully in the Czech Republic. Over there, it is legal to use the whole hemp plant to produce CBD oil, and then imported into France.
What does the ruling mean?
The CJEU ruled that the criminal proceedings against KanaVape weren’t consistent with EU law on the free movement of goods. They stated that: ‘A Member State may not prohibit the marketing of cannabidiol (CBD) lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds.’
In other words, the EU decision said that France’s ban on marketing hemp-derived CBD products contradicted EU law, as the products in question had been produced legally in another EU member state.
EU laws on the free movement of goods do not apply to narcotic drugs, as the marketing of narcotic drugs is banned in all EU member states. The court, therefore, had to establish whether CBD should be regarded as a narcotic in order to determine whether the French authorities had contradicted EU law.
The court concluded that ‘the provisions on the free movement of goods within the European Union (Articles 34 and 36 TFEU) are applicable. This is because the CBD at issue in the main proceedings cannot be regarded as a ‘narcotic drug’.’
In describing its reasoning in deciding whether CBD could be considered a narcotic, the court cited two UN conventions:
The Convention on Psychotropic Substances: The court noted that CBD is not mentioned in this convention.
The Single Convention on Narcotic Drugs:Although this convention makes reference to cannabis extracts, the court observed that interpreting CBD as a drug on this basis would be ‘contrary to the general spirit of that convention and to its objective of protecting ‘the health and welfare of mankind’.’
The court concluded that on this basis, and ‘according to the current state of scientific knowledge’, CBD is not a narcotic drug.
What else did the ruling say?
The ruling stated that a ban by a member state on the marketing of hemp-derived CBD products may be justified ‘by the objective of protecting public health’ but that it ‘must not go beyond what is necessary in order to attain it’.
The court declared that it was for the French national court to assess whether the prohibition in question was justified on those grounds. However, it noted that France hadn’t banned the marketing of synthetic CBD, which has the same properties as CBD and could be used as a substitute for it. The court also stated:
More about the KanaVape case
The KanaVape case began in 2014. The French authorities deemed KanaVape to be contravening French law by selling products containing CBD extracted from whole hemp plants.
In 2018, the Court of Appeal of Aix-en-Provence overturned the initial ruling. This was on the grounds that it contradicted the EU principle of free movement of goods. The case was then referred to the CJEU.
The CJEU sought the guidance of Advocate General Evgeni Tanchev. And, in May 2020, Tanchev was of the opinion that CBD should not be considered a narcotic. This view was not legally binding, but the courts do tend to follow the advice of the Advocate General. Therefore, this was seen as a positive development for the CBD sector.
Unfortunately, this optimism was somewhat dampened in July 2020. The European Commission paused all CBD novel food applications while it considered whether CBD should be regarded as a narcotic. Its preliminary stance was that it should, based on a strict reading of the Single Convention on Narcotic Drugs.
However, the November court ruling definitively contradicted this stance and set a precedent for all EU institutions and member states.
What does the ruling mean for the CBD industry?
The CJEU ruling marked a huge step forward in CBD oil news and is likely to have major ramifications for the CBD industry in Europe.
The European Commission has since abandoned its stance that CBD should be classed as a narcotic. Novel food applications for CBD products have resumed, which clears the way for CBD companies to achieve full legal compliance for their products.
CBD is one of a group of chemical compounds called cannabinoids found in the Cannabis sativa plant species.
Unlike tetrahydrocannabinol (THC), another well-known cannabinoid, CBD does not cause psychotropic effects – it doesn’t get you ‘high’. CBD is typically extracted from hemp, a variety of Cannabis sativa that contains little or no THC.
CBD has seen a surge in popularity recently, as interest has developed in its potential therapeutic benefits. The World Health Organisation has said that CBD is ‘generally well tolerated with a good safety profile’. They’ve also outlined that there is no evidence ‘of any public health-related problems associated with the use of pure CBD’.
We’ll be back soon with more CBD oil news, so watch this space for all the latest developments.
Consumer interest in CBD has risen sharply in the last few years, and that trend looks set to continue.
With the CBD industry on the up, many entrepreneurs are looking to take advantage of the fertile UK market.
If you’ve dreamed of joining them but aren’t sure how to start a CBD business, you’ve come to the right place. We’ve put together a six-step guide to show you how to become a CBD oil distributor in the UK.
Why become a CBD oil distributor in the UK?
Cannabidiol, or CBD, is one of more than 100 cannabinoids found in the Cannabis sativa plant species. Unlike its cousin tetrahydrocannabinol (THC), CBD doesn’t have any psychotropic or intoxicating effects. In other words, it doesn’t get you ‘high’.
The recent rise in consumer interest has been driven by CBD’s potential health and wellness benefits.
Although more research is needed to fully understand its therapeutic properties, studies have so far suggested CBD could be used to relieve pain, aid muscle recovery and treat a variety of complaints. These include insomnia, nausea, acne, asthma, inflammation, anxiety, stress, inflammation.
These potential benefits make CBD one of the most compelling wellness trends to come along in years. Helping people cope with pain, anxiety and other common issues is one of the primary attractions in becoming a CBD oil distributor.
The report suggested that CBD usage was no longer limited to trendsetting millennials but had reached the mainstream. It found that 8-11% of UK adults had tried CBD products, with usage high across classes and age groups.
Intrigued? Here’s how to become a CBD oil distributor in the UK in six steps:
Step 1: Know your CBD market
Before embarking on a CBD business venture it’s essential to understand the market you’ll be operating in.
There are a number of important considerations to be aware of, so do your research carefully.
Legality: Although CBD is legal in the UK, there are some common misconceptions around what’s legal and what isn’t. If you want your CBD business to be successful, it’s vital to stay on the right side of the law.
In a nutshell, CBD products are legal as long as they contain less than 1mg of THC per pack. The 1mg limit applies regardless of the size of the pack.
Products containing more than this amount of CBD would be classed as controlled substances under the Misuse of Drugs Act 1971 (MDA) and would therefore be illegal.
You may have seen some sources quote the legal limit as 0.2% THC – however, this applies to the cultivation of industrial hemp and does not apply to finished CBD products.
Hemp can be cultivated legally in the UK if it contains less than 0.2% THC, although a licence from the Home Office is required. In addition, despite the fact that you may have seen them marketed openly, it is illegal to sell the buds and flowers of hemp plants.
Only the seeds, stalk and stalk fibre can be harvested for commercial purposes. The buds, flowers and leaves are considered cannabis and are therefore a controlled substance under the MDA. To find out more, see our article on CBD laws in the UK.
Sativex, Epidyolex and nabilone are currently the only CBD or cannabis-based medicines that have been licensed in the UK, and can only be prescribed by doctors.
This means that CBD companies must not make claims about the medical benefits of their products.
Rules and regulations: In January 2019 CBD was added to the Novel Food Catalogue, meaning it’s subject to the EU Novel Food Regulation. Foods are considered novel if they haven’t been consumed to a significant level in the UK or EU before May 1997. All novel foods require pre-market safety testing and authorisation before they can be sold in the UK.
Any new business needs a solid business plan, and the CBD industry is no different.
Your business plan is the blueprint for your fledgling CBD business. It should explain your aims, objectives and strategies, and include sales, financial and marketing forecasts.
If you’re looking to secure investment or a business loan, a business plan is absolutely essential. A strong business plan can also help to garner support from suppliers, customers and potential employees.
Building a recognisable and trustworthy brand will inspire customer confidence and help to establish you in the CBD market.
You’ll need to decide whether you as a CBD distributor want to sell purely online or in physical stores. Either way, you’ll need a well-designed website to help you engage with customers and appear reputable.
One of the most important considerations when establishing a CBD brand is to appear professional. The previous under-regulation of the CBD industry has led to confusion and lowered confidence among some consumers, so establishing yourself as a serious brand that customers can trust is key.
When designing your website, logo and other materials, be sure to treat CBD in a mature, respectful way, avoiding imagery that could be linked to cannabis or drug use.
Remember that CBD is a wellness product and cannot be sold as a medicine, so try not to make your branding look too medical.
Perhaps most importantly, show that you’re passionate about CBD. Customers will be much more likely to trust a brand that believes in the product and shows good intentions.
Step 5: Choose your products
As a CBD distributor, sourcing high-quality products should be a top priority. Ensure the products you sell are made in clean conditions in reputable, ISO-certified laboratories.
It’s a good idea to choose products made from organic hemp, to minimise the risk of introducing contaminants like heavy metals.
Lab results should be available for all products, which should show the exact quantities of cannabinoids and other compounds in the product. This will demonstrate that the THC content is within the legal limit and that the product doesn’t contain contaminants.
Make sure all of your products are clearly and correctly labelled with this information.
Now that CBD has been added to the Novel Food Catalogue, it’s vital you adhere to the regulations and ensure compliancy. Leaf Sciences can assist you with this and allow you to focus on growing your business and brand.
Step 6: Join trade organisations
CBD is a fairly new industry in the UK, and the rules and regulations around it are still evolving.
Several trade bodies have been set up in order to establish a framework of standards and best practice, with the aim of making the CBD industry safe, reliable and legally compliant.
UK law on CBD is often met with confusion. CBD oil and other CBD products have seen a surge in popularity in the last few years. However, many people are still unsure whether these products are entirely legal – and there’s also confusion about the regulations they must meet to be sold on the UK market.
In this article, we’ll tell you everything you need to know about CBD oil and UK law.
What is CBD oil?
The Cannabis sativa plant species contains chemical compounds called cannabinoids. Of over 100 different cannabinoids, cannabidiol (or CBD) is just one.
Tetrahydrocannabinol (THC) is the cannabinoid that causes psychoactive effects – the one that gets you ‘high’. CBD doesn’t have this effect.
CBD oil is usually extracted from hemp, a strain of Cannabis sativa containing little or no THC. For thousands of years, hemp has been cultivated and used to make products including:
However, because of its association with cannabis, there is often a lack of clarity over CBD oil and UK law.
What is the UK law on CBD oil?
So, is CBD oil legal in the UK? The short answer is yes – but it’s a little more complicated than that.
CBD oil is legal as long as it doesn’t contain THC. This, along with most other cannabinoids, is a controlled substance under the Misuse of Drugs Act 1971 (MDA). This means that possessing, producing or distributing a product that contains THC is illegal.
CBD is not a controlled substance. However, a CBD product containing traces of THC is a controlled substance under the MDA, unless it meets the ‘exempt product’ criteria in the Misuse of Drugs Regulations 2001 (MDR).
To meet the criteria, a CBD product must not contain more than 1mg of THC per pack. We’ll explain this in more detail below.
1968: The Wootton Report, a Home Office investigation into cannabis, concluded that cannabis was ‘less dangerous than opiates, amphetamines and barbiturates’. They recommended that imprisonment was ‘no longer an appropriate punishment for those who are unlawfully in possession of a small amount’.
1971: The Misuse of Drugs Act came into force. This listed cannabis as a Class B drug and restricted the cultivation of all varieties of the cannabis plant.
2001: The Misuse of Drugs Regulations were introduced. This new legislation permitted cannabis to be cultivated under a licence issued by the Home Office and to be smoked for research purposes.
2010: The Medicines & Healthcare products Regulatory Agency (MHRA) issued a marketing authorisation for Sativex. This cannabis-based medicine is the first to be recognised in the UK as having medicinal properties. Sativex is now available as a prescription-only treatment for multiple sclerosis symptoms.
2018: It became legal for specialist doctors to prescribe cannabis-based medicines for patients with an ‘unmet special clinical need’. The law changed following pressure from parents of children with severe epilepsy, who had benefited from medicinal cannabis.
The flower and bud of the hemp plant are widely available in shops, often sold as ‘tea’ and other products. These products claim to have a high CBD content and ‘legal’ levels of THC.
However, hemp flowers and buds are a controlled substance. The fact they’re openly sold in shops and online is, again, the result of widespread confusion around the law. There’s also a fairly soft stance on enforcement from the UK authorities.
Retailers usually claim their CBD flower and bud products are legal. They often quote the fact that they contain less than 0.2% THC and come from ‘EU approved varieties’ of hemp.
In 2016, the MHRA issued a statement saying: “We have come to the opinion that products containing cannabidiol (CBD) used for medical purposes are a medicine.”
However, they stressed that ‘medicinal products must have a product licence (marketing authorisation) before they can be legally sold, supplied or advertised in the UK’.
Although medical cannabis has been legalised, CBD companies are not allowed to make claims about the medicinal benefits of their products unless they have been granted a medicinal product licence.
Sativex, Epidyolex and nabilone (a synthetic cannabinoid used for treating chemotherapy-induced nausea and vomiting) are currently the only licensed CBD or cannabis-based medicines available in the UK.
Businesses can still sell unlicensed CBD products– and some people may use them medicinally. However, these products are not allowed to be labelled or sold as medicine. MHRA advises anyone using CBD to treat or manage medical conditions to discuss their treatment with their doctor.
CBD Oil and UK Law: Conclusion
CBD oil is not only legal to sell – it’s a thriving business opportunity. With markets growing, there’s never been a better time to get involved.
But as we’ve seen, the laws around CBD are often complex – so it’s helpful to have some expert advice on your side.
Our consultancy service can give you the industry expertise you need, whether it’s help with Novel Foods Regulations or tips on expanding your client base. Get in contact with our team today to find out how we can help you.
This means the public did not consume them to a notable degree in the UK or EU before May 1997. This was when the EU Novel Food Regulation came into force.
Some examples of novel foods are:
Foods consumed elsewhere in the world, like baobab fruit pulp and chia seeds.
Foods made using new processes, like bread treated with UV light to increase vitamin D levels.
New foods, like phytostanols and phytosterols in cholesterol-reducing spreads.
Products that are subject to the Novel Food Regulation are placed on the Novel Food Catalogue based on information provided by EU member states.
The Novel Food Catalogue added CBD to the list in January 2019.
What is novel food authorisation?
Novel foods must undergo a safety assessment and authorisation before they are legally marketed or consumed in the UK.
The food must also fall into one of the following categories:
Animals or plants
Fungi, algae, micro-organisms or cell culture
Minerals or engineered nano-materials
Ingredients that have a new or intentionally modified primary molecular structure
Food produced using a new process that significantly alters the product either nutritionally or in terms of food safety risks
In order to get novel foods authorisation, foods must be safe and must not be misleading to consumers. In addition, they must not replace other foods in a way that would nutritionally disadvantage consumers.
However, the growth has happened with little regulation on the quality or safety of products available. This has resulted in confusion for businesses and lowered consumer confidence.
The new regulatory novel food regulations will pave the way for a safe, sustainable and legally compliant CBD market. This means in future, consumers can feel confident the products they’re buying are of high quality.
What does it mean for CBD companies?
You must have a validated novel food application for any product containing CBD.
On 13 February 2020, the FSA set a new deadline for all CBD companies to submit retrospective applications. By 31 March 2021, all products already on sale had to have a validated application for novel food authorisation in place.
After this, only products with a validated novel food application were legally allowed to stay on the market.
This deadline applied to products that were already on the market on the date of the announcement.
New CBD products that come to the UK market must have full novel food authorisation before their sale. To do this, you must apply for a regulated product authorisation for a novel food.
What does a novel food application involve?
Applying for novel foods authorisation involves preparing a dossier of manufacturing and product information.
You must submit this dossier to the European Commission (or FSA if submitting in the UK from 1 January 2021) through an electronic portal. The dossier must demonstrate that your product is safe for human consumption.
After submission, your application will be evaluated. If you’ve provided sufficient information, it will be validated – this usually takes 2-3 months. This is the stage your application needs to reach before the 31 March 2021 deadline.
Once the EFSA approves the application, they will pass it on to the European Commission. They will then have 7 months to authorise the product and add it to the Union list of novel foods.
How do I prepare a CBD novel food application?
Preparing your dossier involves a variety of product testing and data gathering exercises. Some of these may take as little as 2 weeks, while others can take up to 9 months.
Below is the list of required assessments for CBD products, along with estimates on how long each stage takes:
Full toxicology assessment: 8-9 months, comprising 7-8 months for the assessment followed by one month to produce the data report
Stability assessment: At least 6 months. This should assess a minimum of 6 months’ accelerated stability to support the product’s shelf life. This would be in addition to continued real-time stability testing
Product manufacturing data for a minimum of 5 batches: 5 months. You must independently manufacture and test each batch. Total ADME assessment: 2-3 months
The study will address the missing information identified by the COT. This will include whether CBD can cause liver toxicity or drowsiness, or if it interacts with other drugs. Providing this data will be a key requirement for a successful novel foods dossier.
To minimise animal usage, the study will use a single 90-day rodent study. The resulting data will be available to all participating companies. Companies interested in joining the study can contact the ACI.
Meeting the deadline
All CBD products that were on the market in the UK prior to 13 February 2020 needed to have a validated novel food application by 31 March 2021 to remain on the shelves.
From the submission date, it takes 2-3 months to validate a novel food application. Therefore, to meet the deadline, you should have submitted your dossiers by October 2020 and by December 2020 at the very latest.
Given the timeline above, your data gathering activities should have begun by the end of January 2020 to allow 9 months before submission.
If you’re yet to begin the novel food application process, you should follow the novel food application guidance and CBD guidance from the FSA. You should also make sure the novel food application covers the formulation and usage of your product.
If they aren’t doing this or are unlikely to meet the deadline, you could source a supplier that has already done so to avoid supply chain disruption.
The list can help local authorities enforce regulations on the sale of unregulated foods. It’s also useful for retailers to know the status of suppliers.
The list includes applications which:
Are validated and in the initial stage of the process before going on to the safety assessment
Are ‘on hold’, meaning applicants have started the risk assessment process but haven’t supplied all the information needed
The FSA are regularly reviewing applications made before 31 March to update the list, so it’s worth keeping an eye on.
How will Brexit affect the Novel Food Regulation?
The Novel Food Regulation is an EU regulation. However, the FSA will still require novel foods in the UK to be authorised after the end of the Brexit transition period on 31 December 2020.
Currently, the European Commission and EFSA are responsible for evaluating and authorising novel food applications for the UK.
From 1 January 2021, the FSA and Food Standards Scotland took over responsibility for assessing UK applications. They provide advice to ministers, who then decide if they will authorise novel foods.
For existing authorisations, if your product has been authorised by the European Commission and the appropriate legislation is in place before the end of the transition period, then your authorisation will remain valid in the UK.
However, if you want to make changes to an existing authorisation after 31 December 2020, you’ll need to use the FSA’s authorisation procedure.
For ongoing applications, the FSA states:
“We are finalising procedures for the applications submitted to the EU before the end of the transition period for which the assessment process has not been completed. We will provide guidance in due course.”
How much does a novel food application cost?
There is no fee payable for the application itself, but the cost of testing and reports can be significant.
It could cost just £20,000 if your product uses raw materials that already have a validated novel food application. However, it could cost as much as £350,000 for a complex product that needs a full application.
Novel foods authorisation for CBD products
Worried about novel food regulations or applying for a novel foods authorisation? Leaf Sciences can help. We offer a range of both CBD raw materials and white label products, all covered by a novel food application.
Putting together a full CBD novel food application could involve lots of hassle – and a steep cost. Use our raw materials and white label products to save yourself this difficulty while staying true to your brand.
2019 has been a very exciting year for the CBD industry. There have been lots of changes, and countless people around the world have discovered CBD for themselves. New businesses have flourished, too, and developed exciting products that continue to push the industry forwards.
With things changing at a breakneck pace, the end of the year marks the perfect time to take stock of the industry and look back at some of the key developments. Equipped with a better idea of where we’ve been, we’ll also be better able to predict what 2020 has in store.
The Top CBD Stories From 2019
There have been lots of standout moments when it comes to CBD in 2019. We would love to hear if you have any stories or moments to add to this list – be sure to reach out and let us know if you have anything to add.
1. CBD product sales surged in the UK
In the UK, more than 300,000 people now take CBD on a regular basis. That number has grown significantly over the course of the year, with CBD product sales surging by an incredible 99% by April.
These statistics demonstrate that CBD is enjoying a very high profile in the UK and that it continues to grow in prominence with each passing day. Many analysts believe that Q4 is going to see even faster growth for the latest wellness product, so we’ll be sure to keep you updated with the latest figures as we enter 2020.
As more products continue to hit the market and the general awareness of CBD continues to spread by word of mouth, we can expect this trend to continue throughout the next year.
2. A CBD-based drug for childhood epilepsy was approved for use in the UK
Research into the efficacy and application of CBD is still ongoing. The medical community is working at an impressive pace to explore new potential uses for cannabidiol and this is creating some very interesting findings.
In September this year, the first cannabis-based medicine for childhood epilepsy was given the green light from European authorities. This means that Epidyolex will start to be used throughout the EU thanks to approval from regulators.
This medicine can be used to help children suffering from seizures related to two rare forms of epilepsy. The medicine can be used by the 10,000 children and young adults who currently suffer from the conditions in the UK.
The medicine itself is an oral cannabidiol solution that tastes like strawberries. It is taken twice a day and helps people to better control seizures and achieve a better standard of living.
This same drug was recently legalised in the USA where 15,000 young people are currently treated with it. Chris Tovey is the COO of GW Pharmaceuticals, the UK manufacturer of the drug. In a recent interview, he said that the feedback in the US had been incredibly positive and that he’s optimistic the medicine would be funded by the NHS.
This excellent story is a highlight of the year for people who follow the CBD industry. It’s a great sign that CBD can achieve amazing things, and that the hard work of medical and pharmaceutical companies can change lives.
We will continue to watch this story with interest and we really do hope that families across the UK manage to achieve a better quality of life thanks to this medicine.
3. “Gourmet” CBD-infused jelly beans hit the market
This next story demonstrates how varied and lively this year was in terms of CBD. Earlier this year the creator of the original Jelly Belly beans explained that he has created an exciting new line of “gourmet” CBD-infused jelly beans.
In the interview, David Klein explained that there are currently 38 flavours of jelly beans out there and that candy lovers can access the goodness of CBD with those sweet treats. The product is performing well, and it appears as though the voracious appetite for sweet CBD products means that they are currently sold out.
The success of Klein’s product demonstrates that there really is a growing appetite among customers in the UK for a diverse set of CBD-infused products. This underscores the opportunities that currently exist for businesses looking to diversify their product lines and unlock the potential of CBD.
If you think that 2020 is the year that you would like to capitalise on the potential of CBD, be sure to read our piece on how to create and launch your new CBD product. You’ll find a step-by-step guide that can help to put you ahead of the competition.
4. Ben and Jerry’s announced it has a CBD ice cream in the works
David Klein wasn’t the only quick-thinking expert with the idea for a sweet CBD treat. Ben and Jerry’s – one of the world’s largest ice cream companies – has announced that it has a CBD-infused ice cream ready for production as soon as CBD is legalised in the USA on a federal level.
The CEO of the company explained that the CBD-infused product has been created due to high demand from fans. Again, this shows that there is a strong demand from the average consumer for these types of CBD-infused products.
In terms of lessons that we can learn from this story, you should be sure to listen to your customers. Make sure that you constantly keep an ear to the ground and think of new ways to meet the evolving needs of your customers.
If you haven’t reviewed your products in a while, for instance, you might decide that 2020 is the year to reinvigorate your product range. Who knows, CBD might play a role.
Ben and Jerry’s have the luxury of a very strong brand name. This is going to ensure that as soon as their product hits the market, it’s going to be a huge success and the profile of CBD will hit new heights.
As a smaller player, though, you’ll need to think of new ways to build the reputation of your CBD product. That will help you to secure a foothold within the minds of your customers and boost your revenues. If you want tips, be sure to read our step-by-step guide on how to build the reputation of your CBD product.
5. Walgreens started offering CBD products
Walgreens is a true retail giant and it’s one of the biggest players in the USA. Back in March the company announced that after “thorough review and analysis”, it had decided to stock CBD products in almost 1,500 Walgreens stores in select states.
The product range includes a number of topical creams, sprays and patches. Walgreens explained that by offering those products, the company was striving to meet its goal to make great health and wellbeing products available to its customers.
The product range has been wildly successful since and again, this demonstrates that even the big players in the retail space are beginning to serve the needs of their customers when it comes to CBD.
If you are thinking of making a step into the CBD space, you can draw confidence from the fact that even some of the world’s largest companies are leading the way. If you manage to offer a high-quality CBD product that’s backed by the right strategy, you’ll be able to find success.
6. The world’s first CBD hotel opened in Essex
We have covered the launch of some pretty conventional products so far, but this one was very exciting and it made a big splash in 2019. Earlier this year, Tim Acton opened the world’s first CBD hotel called the Green Coffee Lab in Essex.
The hotel includes a number of different CBD products that delight customers during their stay. Visitors will enjoy CBD-infused shampoo, for instance, as well as access to a number of CBD-infused drinks and snacks. Light fittings were made using only hemp, too.
In his interview with The Independent, Tim explains that he believes “CBD has become accessible in terms of the stigma that cannabis had.” He believes that a shift in perception has helped his hotel to launch successfully.
This was a big story in 2019 and it demonstrates that experiential products are also a big hit with customers. When it comes to CBD, you don’t have to restrict yourself to physical products – you could think of new ways to help people incorporate CBD into their lives.
7. CBD skin care products grew in prominence
The skincare industry is thriving and CBD has cemented itself as a potent beauty ingredient in the eyes of customers. Customers love to use this product and we’re going to see this trend extend into 2020.
In the UK, Holland and Barrett is one of the country’s most prominent stockists and it is really leading the way when it comes to the growth of CBD within the health and beauty space. Celebrity endorsements are also pushing the profile of CBD when it comes to skincare, too.
If you offer creams and lotions, you might want to consider bolstering your existing product line with a CBD-infused offering. This could help you to capture part of this impressive growth and serve your customers with the products they love.
This year, the first CBD cafe launched in Scotland too. Stirling city centre is now home to the CBD cafe and it gives locals the benefits of CBD alongside beautiful drinks and snacks.
The opening of this cafe demonstrates that there are lots of diverse opportunities for entrepreneurs within the UK. CBD is growing immensely in terms of popularity and there are high street opportunities.
Perhaps you’re interested in launching a thriving CBD business in 2020. There are lots of similar stories that have emerged this year, so there are many opportunities for you to learn from others and launch with confidence.
9. A number of celebrities endorsed CBD
The profile of CBD reached new heights this year due to a number of high-profile celebrity endorsements. Celebrities have been using their star power to champion the growth of CBD in general, and they’ve also been pushing their own products into the public eye.
Stars like Kim Kardashian and Willie Nelson have seen the potential of CBD and they’ve decided to lend their names to various products. This brings a lot of eyes on CBD products in general and it means we can expect customer demand to expand even further.
As you can see, 2019 was quite the year for CBD. We are confident that 2020 is going to be equally as exciting, and we hope that you’ll be able to capture a part of this immense growth.
If you are going to make a step into the CBD space, you’ll need the best CBD in the business to back you up. The best wholesale CBD can help you to grow the reputation of your product and delight your customers by meeting their needs.
We know that you want nothing but the best. That’s why you should shop with CBD Capital. It’s our pleasure to offer the very best isolate in the world so that you can take your products to new heights. Our global approach means that you’ll only get the best product that has been extracted using the most efficient extraction techniques.
How to Use Celebrity CBD Endorsements to Sell Your CBD Products
Celebrity endorsements are a mainstay of modern marketing, and now they’re making an impact within the CBD industry too. As more people open their eyes to the benefits of CBD, they’re spreading the word – and this goes for the rich and famous too.
With the UK CBD market projected to be worth £1bn each year from 2025 onwards, we’re taking a look at how celebrity endorsements could help you sell your CBD products.
Why Grand Celebrity CBD Endorsements Matter Even To Smaller CBD Businesses
Celebrity endorsements are very effective and they absolutely have the potential to influence sales.
There are a few reasons that celebrity endorsements are so effective. Here’s a closer look at five key reasons:
Celebrities and their star power act as a natural pull for consumers. People pay attention when they see a familiar face and listen to what that person is saying.
Celebrities act as taste makers. For better or worse, people often want to emulate the style and behaviour of iconic celebrities.
Celebrities are often admired by a range of different groups.
When a celebrity lends their weight to a product or cause, its perceived legitimacy immediately increases.
We see countless adverts every day – the ones that we remember are often the ones featuring a recognisable face.
In the world of CBD, celebrities are currently backing cannabidiol as opposed to particular brands. This is because the CBD industry is in its infancy and those celebrities want to push CBD in general so that their own products and initiatives gain ground.
Nike spends an incredible $475 million each year on celebrity endorsements, and they are clearly very effective. Naturally, companies in smaller, emerging industries are likely to follow suit; we expect to see more and more celebrity endorsements of CBD in the coming years.
These endorsements are great news for your CBD business. Each time that a celebrity goes on record to endorse CBD, your own stock increases, along with consumer demand.
You should be sure to capitalise on these endorsements and communicate them to your customers.
The Most Significant Celebrity CBD Endorsements
Before we get into how to make the most of them, let’s take a closer look at some major celebrity CBD endorsements.
When it comes to celebrities, few are quite as influential or impactful as Kim Kardashian. The star has a real love affair with CBD, and she has taken to Instagram on numerous occasions to tell her 150 million followers all about it.
She has said in interviews that CBD “saved her life” and helped her to find reprieve from her demanding schedule. She uses CBD gummies as a natural way to get some sleep, and she also threw a CBD-themed baby shower. Guests were given CBD chocolates, oils, lotions and face masks to unwind and celebrate the arrival of Kim’s child.
The glamorous star explained that CBD helped to solve her aches and pains during a demanding run of Broadway performances. She explained that she wanted to avoid using too many painkillers, so she found a natural solution.
Megan played a huge role in leading the US Women’s National Team to international triumph earlier this year. The winger has a fantastic personality and she has become an inspiration for many women.
The superstar is a leading face of the equal pay movement and she’s an LGBT icon. She has recently forged close ties with Medi, a company that creates CBD sports recovery products targeted at athletes.
Megan’s endorsement will open up the world of CBD to an entirely new range of customers.
Jennifer Aniston is undoubtedly one of the world’s biggest stars. She has also become a lifestyle icon too and recently explained how she uses CBD to deal with pain, anxiety and stress.
The Friends star is also widely admired for her natural beauty, and many fans will undoubtedly make a connection between CBD and her youthful appearance.
Willie Nelson is a music icon and he recently launched his very own CBD brand. Willie’s Remedy sells a range of hemp-based wellness products and his name plays a huge role in the acquisition of new customers.
The brand has an artisanal vibe to it, and by all accounts the brand is doing very well. Again, Willie’s endorsement demonstrates how celebrities can use their star power to open up new interest among different groups of customers.
Rob Gronkowski is an ex-NFL superstar who played for the New England Patriots. The superstar is also famous for his business savvy, and he is now partnering with Abacus, a CBD company.
Rob Gronkowski is one of a few key athletes pushing the reputation of CBD in the sporting world. He is making big strides to help other athletes unlock the potential of CBD.
Nate Diaz is one of the biggest stars in the UFC. Fans love him for his authenticity and unparalleled cardio. He is renowned for his ability to keep on going and tire out his opponents.
The UFC star recently launched a nutritional supplement that is based around CBD; it helps athletes relieve the aches and pains associated with the intense training required to succeed in the UFC.
Mark Wahlbeg is an Oscar-nominated actor and former rapper. His career recently took another twist when he invested in AQUAhydrate, a business that sells alkaline water infused with CBD.
The business is entering full swing now, and Mark’s involvement will likely be a significant boost for the company. This shows that lots of celebrities are going beyond mere endorsements and aiming to create their own brands.
How to Use Celebrity CBD Endorsements to Sell Your Products
Those celebrities have their own reasons for making their endorsements, but you can absolutely use them to support the reputation of CBD as a whole.
Here’s a closer look at some ways that you can use celebrity endorsements of CBD in general to sell more products:
Communicate the news
Whenever a celebrity makes a significant endorsement of CBD, you should consider sharing that with your customers. If you have a newsletter or blog, why not write up a quick story?
This could be a way to build a rapport with your customers and encourage them to make their purchase.
Mention relevant examples
If you are selling CBD products, there’s a good chance that you’ll have close contact with a number of customers. If you are trying to educate them about the popularity and safety of CBD, you could mention some relevant celebrity endorsements.
Let’s imagine, for instance, that you sell a CBD face cream that gets amazing results for your customers. A customer comes into your store and asks about the efficacy of your product – you could mention that certain celebrities use similar products to achieve those results.
This is an interesting sales technique and it is genuinely useful for your customer. They will appreciate the information and it might just help them to make a great choice and purchase their CBD products.
The great news is that with so many diverse endorsements out there, it’s easy to find a great example. If you sell a CBD supplement that helps to restore a person post-workout, you could point to Nick Diaz’s regular CBD use. Get creative!
Guide your messaging
The nascent CBD industry is an exciting one. The freshness of the industry means that it can be difficult for you to market your products, though. You might struggle to find your feet and understand who is purchasing your products and why.
If that’s the case, celebrity endorsements can give you lots of interesting inspiration to guide your marketing. You could use a particular endorsement to build a buyer persona, for instance.
Let’s imagine that you look at Kim Kardashian’s statements about CBD; you can start to paint a picture of the potential customer who appreciates Kim Kardashian and sympathises with her statement. This can help you to target your marketing materials more effectively.
It’s very important that you make a clear distinction between general celebrity endorsements of CBD and those that are related to your specific product.
If you believe that your product has what it takes, you may want to pursue your own celebrity endorsements! You should work hard to build the reputation and profile of your products; if you develop a fantastic reputation, the future could be very bright.
You might want to explore the potential of influencer marketing too. The principle is the same – you can leverage star power to connect with new potential audiences.
Use the CBD that celebrities love
If you are looking for the best wholesale CBD that makes its way into many of the world’s finest CBD products, you’ll want to shop with Leaf Sciences.
We offer the purest CBD on the market and we truly believe in the potential of CBD to improve quality of living for people around the world. That’s why we work incredibly hard to use an extensive global supply chain that provides us with the finest materials.
Our distillation methods are unbeatable. These techniques are accredited by multiple governments and they are capable of producing pharmaceutical-grade products that can be used by the international CBD industry.
If you are interested in using our wholesale CBD in your products, get in touch with us today to discuss how we can meet your needs.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.